Why some people have stronger natural defences against SARS-COV-2 

A team of scientists at the MRC University of Glasgow Centre for Virus Research has revealed key research into the natural human antiviral defences against SARS-CoV-2, the virus that causes Covid-19.  

In the study, the scientists reveal that some people have a version of a gene, called OAS1, that potently inhibits SARS-CoV-2 and that while some people can express a more protective ‘prenylated’ version of the OAS1 gene, other people express a version of this gene which does not detect SARS-CoV-2. 

Inside cells, coronaviruses hide and replicate inside vesicles coated with lipid (fat). Prenylation is the addition of a single molecule of lipid (fat) to a protein – and it’s this technical difference that allows prenylated OAS1 to ‘seek out’ the invading virus and ‘sound the alarm’. The study found that, in hospitalised patients, expression of a prenylated version of this gene was associated with protection from severe Covid-19, which suggests this antiviral defense is a major component of a protective antiviral response; and is likely to have offered protection to many people during the course of the pandemic.  

The study also found that hospitalised Covid-19 patients with the ‘bad’ form of OAS1 had worse clinical outcomes compared to those who expressed the protective prenylated version of OAS1. Severe disease was significantly more frequent with ICU admission or death being approximately 1.6 times more likely in these patients.  

The researchers also found that, approximately 55 million years ago, there was a removal of this protective gene in horseshoe bats – the presumed source of SARS-CoV-2) – so therefore SARS-CoV-2 never had to adapt to evade this defence.  

As the protective prenylated OAS1 gene is widespread in animals, the billions of people that lack this protective gene could make humans particularly vulnerable to the spill over of coronaviruses from horseshoe bats.  

Sam Wilson, Professor at the Centre for Virus Research at the University of Glasgow, said: “We know viruses adapt, and even SARS-CoV-2 has likely adapted to replicate in the animal reservoir(s) in which it circulates. Cross-species transmission to humans exposed the virus SARS-CoV-2 to a new repertoire of antiviral defences, some of which SARS-CoV-2 may not know how to evade. “What our study shows us is that the coronavirus that caused the SARS outbreak in 2003 learned to evade prenylated OAS1. If SARS-CoV-2 variants learn the same trick, they could be substantially more pathogenic and transmissible in unvaccinated populations. This reinforces the need to continually monitor the emergence of new SARS-CoV-2 variants.” 

Image credit: Quinten Braem 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free